Let’s play not the Blame Game or the Plame Game (which involved the outing of CIA operative Valerie Plame in 2007) but the Flame Game with lead EpicentRx therapies, RRx-001 (nibrozetone) and AdAPT-001. The object is to determine under what circumstances or conditions these therapies will activate or FLAME ON – and by activate we mean have a therapeutic effect on.
For context it helps to remember that based on both clinical and preclinical evidence 1) RRx-001 (nibrozetone) is broadly active because of its trispecific mechanisms of action i.e., nitric oxide donation under hypoxia, NLRP3 inflammasome inhibition, and Nrf2 activation and 2) AdAPT-001 is also broadly active because TGF-β, the cytokine that it traps or eliminates, controls so many important functions such cell cycle progression, immune suppression, and injury repair.
With that in mind, can you guess the answers to these categories in advance?
Hypoxia: FLAME ON for RRx-001
Fibrosis: FLAME ON for both therapies
Dysplasia: FLAME ON for both therapies
Inflammation: FLAME ON for RRx-001
Warts: Possibly FLAME ON for AdAPT-001
Cerebral malaria: FLAME ON for RRx-001
Myocardial infarction: FLAME ON for RRx-001
Renal failure: FLAME ON for RRx-001
Tumors: FLAME ON for both therapies
Oral mucositis: FLAME ON for RRx-001
Diarrhea: FLAME ON for RRx-001
Endometriosis: FLAME ON for RRx-001, unknown for AdAPT-001
Neurodegenerative diseases: FLAME ON for RRx-001
COVID-19: FLAME ON for RRx-001
Heart failure: FLAME ON for RRx-001
Pulmonary hypertension: FLAME ON for both therapies
Alopecia areata: Probably FLAME ON for RRx-001
Allergies: Unknown for RRx-001
Vitiligo: Possibly FLAME ON for both therapies
Non-alcoholic fatty liver disease: FLAME ON for RRx-001
Synonymous with “Flame Game” is “Tame Game” because both RRx-001 and AdAPT-001 have the potential to “tame” several diseases of unmet medical need as well as side effects from other therapies.